Etanercept biosimilar associated with Guillain-Barré syndrome: insights from a case
Keyword(s):
Anti-tumor necrosis factor drugs are used routinely according to treatment guidelines for several chronic rheumatologic problems. However, a rare and usually unpredictable adverse drug reaction namely peripheral nervous system demyelination is being increasingly recognized. Biosimilars are gaining momentum especially in countries like India. Hence, we report a case of Guillain-Barré syndrome secondary to an etanercept biosimilar, probably the first case reported so far.
2011 ◽
Vol 39
(2)
◽
pp. 1537-1540
◽
2017 ◽
Vol 310
◽
pp. 46-50
◽
2019 ◽
Vol 337
◽
pp. 577064
◽
2016 ◽
Vol 21
(1)
◽
pp. 103-112
◽
1995 ◽
Vol 29
(4)
◽
pp. 381-383
◽